Inovio Pharmaceuticals (INO) Non-Current Deffered Revenue (2010 - 2022)
Inovio Pharmaceuticals (INO) posted Non-Current Deffered Revenue of $56935.0 for Q2 2022, down 6.12% sequentially from $60648.0 in Q1 2022, and down 20.69% YoY from $71788.0 in Q2 2021.
Inovio Pharmaceuticals (INO) Non-Current Deffered Revenue (2010 - 2022) Analysis & Trends
Inovio Pharmaceuticals has reported Non-Current Deffered Revenue for 13 years, with the latest figure at $56935.0 in Q2 2022.
- Quarterly Non-Current Deffered Revenue fell 20.69% year-over-year to $56935.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $56935.0 (down 20.69% YoY) and the FY2021 annual result came in at $64361.0, down 18.75% from the prior year.
- Non-Current Deffered Revenue eased to $56935.0 in Q2 2022 per INO's latest filing, from $60648.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $8.7 million in Q3 2018 and troughed at $56935.0 in Q2 2022.
- A 5-year average of $1.0 million and a median of $93497.5 in 2020 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2018 and 2019: Non-Current Deffered Revenue soared 5168.82% in 2018, then slumped 98.81% in 2019.
- Over 5 years, Non-Current Deffered Revenue stood at $8.5 million in 2018, then plunged by 98.81% to $101567.0 in 2019, then decreased by 22.01% to $79214.0 in 2020, then fell by 18.75% to $64361.0 in 2021, then dropped by 11.54% to $56935.0 in 2022.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $56935.0, $60648.0, and $64361.0 for Q2 2022, Q1 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 56,935.00 |
| Mar 31, 2022 | 60,648.00 |
| Dec 31, 2021 | 64,361.00 |
| Sep 30, 2021 | 68,075.00 |
| Jun 30, 2021 | 71,788.00 |
| Mar 31, 2021 | 75,501.00 |
| Dec 31, 2020 | 79,214.00 |
| Sep 30, 2020 | 82,927.00 |
| Jun 30, 2020 | 86,641.00 |
| Mar 31, 2020 | 100,354.00 |
| Dec 31, 2019 | 101,567.00 |
| Sep 30, 2019 | 124,105.00 |
| Jun 30, 2019 | 116,630.00 |
| Mar 31, 2019 | 141,803.00 |
| Dec 31, 2018 | 8.52 Mn |
| Sep 30, 2018 | 8.67 Mn |
| Jun 30, 2018 | 175,157.00 |
| Mar 31, 2018 | 203,322.00 |
| Dec 31, 2017 | 215,853.00 |
| Sep 30, 2017 | 164,604.00 |